Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Reconceptualization of the Molecular Mechanism by Which Sodium-Glucose Cotransporter 2 Inhibitors Reduce the Risk of Heart Failure Events.

× No keyword cloud information.

12 in total

Review 1. Sodium-glucose Co-transporters-2 Inhibitors and Heart Failure: State of the Art Review and Future Potentials.

Authors: Eri Toda Kato; Takeshi Kimura
Journal: Int J Heart Fail Date: 2020-01-13

Review 2. Platelet Effects of Anti-diabetic Therapies: New Perspectives in the Management of Patients with Diabetes and Cardiovascular Disease.

Authors: Annunziata Nusca; Dario Tuccinardi; Silvia Pieralice; Sara Giannone; Myriam Carpenito; Lavinia Monte; Mikiko Watanabe; Ilaria Cavallari; Ernesto Maddaloni; Gian Paolo Ussia; Silvia Manfrini; Francesco Grigioni
Journal: Front Pharmacol Date: 2021-05-12 Impact factor: 5.810

3. Effects of canagliflozin in patients with type 2 diabetes and chronic heart failure: a randomized trial (CANDLE).

Authors: Atsushi Tanaka; Itaru Hisauchi; Isao Taguchi; Akira Sezai; Shigeru Toyoda; Hirofumi Tomiyama; Masataka Sata; Shinichiro Ueda; Jun-Ichi Oyama; Masafumi Kitakaze; Toyoaki Murohara; Koichi Node
Journal: ESC Heart Fail Date: 2020-04-29

4. Two-Dimensional and Three-Dimensional Transthoracic Echocardiography as Predictive and Prognostic Indicators of All-Cause Mortality in Heart Failure with Reduced Ejection Fraction in Patients with Ischemic Heart Disease.

Authors: Aixia Lu; Haibo Fan; Jinfeng Xu; Jun Li; Honglei Zhao
Journal: Med Sci Monit Date: 2020-06-07

5. Nuclear miR-320 Mediates Diabetes-Induced Cardiac Dysfunction by Activating Transcription of Fatty Acid Metabolic Genes to Cause Lipotoxicity in the Heart.

Authors: Huaping Li; Jiahui Fan; Yanru Zhao; Xiaorong Zhang; Beibei Dai; Jiabing Zhan; Zhongwei Yin; Xiang Nie; Xiang-Dong Fu; Chen Chen; Dao Wen Wang
Journal: Circ Res Date: 2019-10-22 Impact factor: 17.367

6. Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: A Meta-analysis.

Authors: Darren K McGuire; Weichung J Shih; Francesco Cosentino; Bernard Charbonnel; David Z I Cherney; Samuel Dagogo-Jack; Richard Pratley; Michelle Greenberg; Shuai Wang; Susan Huyck; Ira Gantz; Steven G Terra; Urszula Masiukiewicz; Christopher P Cannon
Journal: JAMA Cardiol Date: 2021-02-01 Impact factor: 14.676

Review 7. SGLT2 Inhibitors and Their Antiarrhythmic Properties.

Authors: Ewald Kolesnik; Daniel Scherr; Ursula Rohrer; Martin Benedikt; Martin Manninger; Harald Sourij; Dirk von Lewinski
Journal: Int J Mol Sci Date: 2022-01-31 Impact factor: 5.923

8. Lessons learned from the DAPA-HF trial concerning the mechanisms of benefit of SGLT2 inhibitors on heart failure events in the context of other large-scale trials nearing completion.

Authors: Milton Packer
Journal: Cardiovasc Diabetol Date: 2019-10-04 Impact factor: 9.951

9. Effects of Dapagliflozin and Sitagliptin on Insulin Resistant and Body Fat Distribution in Newly Diagnosed Type 2 Diabetic Patients.

Authors: Yue Sun; Dong Yan; Zirui Hao; Lijuan Cui; Guiping Li
Journal: Med Sci Monit Date: 2020-04-02

Review 10. Sodium-Glucose Co-transporter 2 Inhibitors in the Failing Heart: a Growing Potential.

Authors: Dulce Brito; Paulo Bettencourt; Davide Carvalho; Jorge Ferreira; Ricardo Fontes-Carvalho; Fátima Franco; Brenda Moura; José Carlos Silva-Cardoso; Rachel Tavares de Melo; Cândida Fonseca
Journal: Cardiovasc Drugs Ther Date: 2020-06 Impact factor: 3.947